EBV and MSI Status in Gastric Cancer: Does It Matter?

Catarina Neto do Nascimento, Luís Mascarenhas-Lemos, João Ricardo Silva, Diogo Sousa Marques, Catarina Ferreira Gouveia, Ana Faria, Sónia Velho, Rita Garrido, Rui Maio, Andreia Costa, Patrícia Pontes, Xiaogang Wen, Irene Gullo, Marília Cravo, Fátima Carneiro

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)
33 Downloads (Pure)


We investigated the impactof microsatellite instability (MSI) and Epstein–Barr virus (EBV) status in gastric cancer (GC), regarding response to perioperative chemotherapy (POPChT), overall survival (OS), and progression-free survival (PFS). We included 137 cases of operated GC, 51 of which were submitted to POPChT. MSI status was determined by multiplex PCR and EBV status by EBV-encoded RNA in situ hybridization. Thirty-seven (27%) cases presented as MSI-high, and seven (5.1%) were EBV+. Concerning tumor regression after POPChT, no differences were observed between the molecular subtypes, but females were more likely to respond (p = 0.062). No significant differences were found in OS or PFS between different subtypes. In multivariate analysis, age (HR 1.02, IC 95% 1.002–1.056, p = 0.033) and positive lymph nodes (HR 1.82, IC 95% 1.034–3.211, p = 0.038) were the only prognostic factors for OS. However, females with MSI-high tumors treated with POPChT demonstrated a significantly increased OS compared to females with MSS tumors (p = 0.031). In conclusion, we found a high proportion of MSI-high cases. MSI and EBV status did not influence OS or PFS either in patients submitted to POPChT or surgery alone. However, superior survival of females with MSI-high tumors suggests that sex disparities and molecular classification may influence treatment options in GC.

Original languageEnglish
Article number74
Issue number1
Publication statusPublished - Jan 2023


  • Epstein–Barr virus
  • females
  • gastric cancer
  • gender
  • microsatellite instability
  • molecular subtype
  • neoadjuvant chemotherapy
  • perioperative chemotherapy predictor
  • prognosis


Dive into the research topics of 'EBV and MSI Status in Gastric Cancer: Does It Matter?'. Together they form a unique fingerprint.

Cite this